Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The primary objective for this study is to determine if the addition of filibuvir to a
standard regimen of peginterferon/ribavirin (pegIFN/RBV) significantly increases the
proportion of subjects who achieve a sustained viral response (SVR) compared to
peginterferon/ribavirin (pegIFN/RBV) therapy alone.